NovaBay Pharma (NBY) Commences NVC-422 Phase 2b
Up)
NovaBay Pharmaceuticals, Inc. (AMEX: NBY), has selected multiple organizations to manage the Company's Phase 2b clinical study of NVC-422 for the treatment of adenoviral conjunctivitis, a form of "pink eye." This global study is anticipated to enroll up to 450 patients with confirmed adenoviral conjunctivitis at investigational sites in India, Brazil, and the United States.
NovaBay's Phase 2b clinical trial of NVC-422 for the treatment of adenoviral conjunctivitis is expected to begin enrolling patients in Q212.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
NovaBay's Phase 2b clinical trial of NVC-422 for the treatment of adenoviral conjunctivitis is expected to begin enrolling patients in Q212.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Sucampo Pharma (SCMP) Updates on Protective Effect of SPI-8811 in NSAID-Induced GMI
- Perrigo (PRGO) Gets FDA Approval for Generic Gynazole 1
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
